WuXi AppTec Leads Strategic Investment in Insilico Medicine to Accelerate Drug Discovery Using Next-Generation Artificial Intelligence
The round was led by WuXi AppTec's
"WuXi AppTec is a leading global pharmaceutical and technology platform company and it has been a privilege to work hand-in-hand with WuXi AppTec's world-class chemists and biologists, who routinely solve some of the most complex challenges presented by the global pharmaceutical industry," said Dr.
The funding is intended to enhance Insilico Medicine's work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques, as well as to expand a variety of the biomarker discovery initiatives.
"WuXi AppTec and Insilico Medicine share a mutual vision that artificial intelligence and machine learning will optimize the drug discovery process by increasing the probability of success at the pre-clinical level," said Dr.
The transaction has been a joint effort between WuXi AppTec's
"With the investment in Insilico Medicine, we are now taking our partnership to the next level by establishing a closer integration within WuXi AppTec's own research capabilities to better serve the biopharmaceutical industry," said Mr.
About WuXi AppTec
WuXi AppTec (603259, SH) is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi AppTec is committed to enabling innovative collaborators to bring innovative healthcare products to patients, and to fulfilling WuXi's dream that "every drug can be made and every disease can be treated."
About
About
Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of ageing and creates the opportunity to develop therapeutics now that can slow, halt or potentially reverse elements of ageing.
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in
Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. For more information on Insilico Medicine, please visit http://insilico.com.
Media Contacts:
WuXi AppTec
Insilico Medicine
View original content with multimedia:http://www.prnewswire.com/news-releases/wuxi-apptec-leads-strategic-investment-in-insilico-medicine-to-accelerate-drug-discovery-using-next-generation-artificial-intelligence-300663758.html
SOURCE Insilico Medicine
Black Forest fire: 5 years later, residents warily eye looming danger
Butler County bracing for health insurance hikes
Advisor News
- What to discuss during the first retirement planning meeting
- Inflation, competing priorities and uncertainty erode retirement security
- As health premiums rise, 1 in 8 workers cut retirement savings
- CT governor’s candidates claims: What’s true, and what’s misleading
- Retaining clients by giving them a memorable experience
More Advisor NewsAnnuity News
- National Life Group expands annuity portfolio
- AM Best to Join Life/Annuity Insurance-Focused Panel Discussion at Capitol Forum Event
- USAA Earns No. 1 Ranking in JD Power Individual Annuity Study for the Third Consecutive Year
- How flexible annuities fit today’s retirement portfolios
- Foresters Financial appoints Tom Ross as chief distribution officer for U.S. annuity sales
More Annuity NewsHealth/Employee Benefits News
- Obamacare dealt yet another blow as premiums rise again
- CONSUMER ADVISORY: OPEN ENROLLMENT STARTS NOV. 1: COMPARE OPTIONS AND FIND OUT HOW TO SAVE
- GOVERNOR SPANBERGER CELEBRATES COURT RULING PROTECTING HEALTHCARE COVERAGE FOR VIRGINIANS WITH SERIOUS ILLNESSES
- Kenai renews employee health coverage despite $792K jump in costs
- Healthcare navigator: More people are dropping insurance or choosing higher-deductible plans
More Health/Employee Benefits NewsLife Insurance News